Takara Bio (FRA:TF2) EPS without NRI: €-0.34 (TTM As of Mar. 2026)


FRA:TF2 Takara Bio Inc FRA:TF2
50 GF Score
Price €5.95
GF Value €4.47
! 6 Warning Signs
View Full Analysis

What is Takara Bio EPS without NRI?

Takara Bio FRA:TF2 50 EPS without NRI is €-0.34 as of Mar. 2026. GuruFocus rates FRA:TF2 with a GF Score™ of 50/100 and a GF Value™ of €4.47. The stock has 6 warning signs investors should review. Among 1,166 Biotechnology companies, Takara Bio ranks worse than 85763.21% on this metric.

Takara Bio's earnings per share without non-recurring items for the three months ended in Mar. 2026 was €-0.02. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.34.

During the past 12 months, Takara Bio's average earnings per share (NRI) Growth Rate was -572.70% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Takara Bio's EPS without NRI or its related term are showing as below:

During the past 13 years, Takara Bio's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 68.40% per year. The lowest was -58.20% per year. And the median was 7.10% per year.

FRA:TF2's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.65
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Takara Bio's EPS (Diluted) for the three months ended in Mar. 2026 was €0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.46.

Takara Bio's EPS (Basic) for the three months ended in Mar. 2026 was €0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.46.


Takara Bio  (FRA:TF2) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Takara Bio EPS without NRI Related Terms


Takara Bio EPS without NRI Historical Data

* Premium members only.

The historical data trend for Takara Bio's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takara Bio EPS without NRI Chart

Takara Bio Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.31 0.91 0.10 0.08 -0.32

Takara Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 -0.08 -0.12 -0.12 -0.02

FRA:TF2 vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Takara Bio's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takara Bio PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Takara Bio's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Takara Bio's PE Ratio without NRI falls into.


FRA:TF2
50GF Score
Takara Bio Inc FRA:TF2
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takara Bio EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-0.34 mean?
Takara Bio (FRA:TF2) has a EPS without NRI of €-0.34 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Takara Bio and its competitors. According to the industry distribution chart, Takara Bio ranks #999999 out of 1166 companies in the Biotechnology industry.
Is Takara Bio's EPS without NRI too high?
Takara Bio's current EPS without NRI is €-0.34. Based on the distribution chart, Takara Bio ranks #999999 out of 1166 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Takara Bio has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #999999 out of 1166 companies for EPS without NRI. This places Takara Bio in the lower half of its industry. The industry median EPS without NRI is 16.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.65, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Takara Bio and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takara Bio's current EPS without NRI is €-0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Takara Bio (FRA:TF2) has a current EPS without NRI of €-0.34. The stock's GF Value™ is €4.47, compared to a current price of €5.95 — trading 33.1% above its estimated fair value. The current EPS without NRI is €-0.34. Takara Bio's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current EPS without NRI is €-0.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takara Bio (FRA:TF2) Overvalued in 2026?

Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued. The current stock price of €5.95 is trading 33.1% above its estimated GF Value™ of €4.47.

Key valuation signals for FRA:TF2:

  • EPS without NRI: €-0.34
  • GF Value™: €4.47 vs. price of €5.95 (33.1% above fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Takara Bio Business Description

Other Exchanges 4974:Japan
Address Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
50GF Score

Get the complete analysis for FRA:TF2

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.95
Price
€4.47
GF Value